Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2020 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10362/94248 |
Resumo: | This work was supported by a Research Grant from the InvestigatorInitiated Studies program of Merck Sharp & Dohme (Grant No. 56078). The sponsor did not interfere with the study question, analysis or interpretation of results. AS is supported by a doctoral grant from Fundação para a Ciência e Tecnologia (Foundation for Science and Technology) (SFRH/BD/108246/2015). |
| id |
RCAP_4324464cf5abd23685dc739a40817219 |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/94248 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritisgoing beyond BASDAISDG 3 - Good Health and Well-beingThis work was supported by a Research Grant from the InvestigatorInitiated Studies program of Merck Sharp & Dohme (Grant No. 56078). The sponsor did not interfere with the study question, analysis or interpretation of results. AS is supported by a doctoral grant from Fundação para a Ciência e Tecnologia (Foundation for Science and Technology) (SFRH/BD/108246/2015).OBJECTIVES: To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (≥2.1) and BASDAI (≥4) definitions of high disease activity) were compared regarding baseline characteristics and response to bDMARDs at 3 and 6 months estimated in multivariable regression models. RESULTS: Of the 594 patients included, the majority (82%) had both BASDAI≥4 and ASDAS ≥2.1. The frequency of ASDAS ≥2.1, if BASDAI<4 was much larger than the opposite (ie, ASDAS <2.1, if BASDAI≥4): 62% vs 0.8%. Compared to patients fulfilling both definitions, those with ASDAS ≥2.1 only were more likely to be male (77% vs 51%), human leucocyte antigen B27 positive (79% vs 65%) and have a higher C reactive protein (2.9 (SD 3.5) vs 2.1 (2.9)). Among bDMARD-treated patients (n=359), responses across subgroups were globally overlapping, except for the most 'stringent' outcomes. Patients captured only by ASDAS responded better compared to patients fulfilling both definitions (eg, ASDAS inactive disease at 3 months: 61% vs 25% and at 6 months: 42% vs 25%). CONCLUSION: The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally 'captured' patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS≥2.1 as a criterion for treatment decisions.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNMarona, JoseSepriano, AlexandreRodrigues-Manica, SantiagoPimentel-Santos, FernandoMourão, Ana FilipaGouveia, NéliaBranco, JaimeSantos, HelenaVieira-Sousa, ElsaVinagre, FilipeTavares-Costa, JoãoRovisco, JoãoBernardes, MiguelMadeira, NathalieCruz-Machado, RitaRoque, RaquelSilva, Joana LeiteMarques, Mary LucyFerreira, Raquel MiriamRamiro, Sofia2020-03-13T23:36:13Z2020-012020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/94248eng2044-6055PURE: 17301328https://doi.org/10.1136/rmdopen-2019-001145info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:42:18Zoai:run.unl.pt:10362/94248Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:37:55.015500Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis going beyond BASDAI |
| title |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| spellingShingle |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis Marona, Jose SDG 3 - Good Health and Well-being |
| title_short |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| title_full |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| title_fullStr |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| title_full_unstemmed |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| title_sort |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis |
| author |
Marona, Jose |
| author_facet |
Marona, Jose Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Santos, Helena Vieira-Sousa, Elsa Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Cruz-Machado, Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| author_role |
author |
| author2 |
Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Santos, Helena Vieira-Sousa, Elsa Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Cruz-Machado, Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) Centro de Estudos de Doenças Crónicas (CEDOC) RUN |
| dc.contributor.author.fl_str_mv |
Marona, Jose Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Santos, Helena Vieira-Sousa, Elsa Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Cruz-Machado, Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| dc.subject.por.fl_str_mv |
SDG 3 - Good Health and Well-being |
| topic |
SDG 3 - Good Health and Well-being |
| description |
This work was supported by a Research Grant from the InvestigatorInitiated Studies program of Merck Sharp & Dohme (Grant No. 56078). The sponsor did not interfere with the study question, analysis or interpretation of results. AS is supported by a doctoral grant from Fundação para a Ciência e Tecnologia (Foundation for Science and Technology) (SFRH/BD/108246/2015). |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020-03-13T23:36:13Z 2020-01 2020-01-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/94248 |
| url |
http://hdl.handle.net/10362/94248 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
2044-6055 PURE: 17301328 https://doi.org/10.1136/rmdopen-2019-001145 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799137995785240576 |